These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19021049)

  • 1. Preclinical versus clinical drug combination studies.
    Chou TC
    Leuk Lymphoma; 2008 Nov; 49(11):2059-80. PubMed ID: 19021049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational approach to the clinical protocol design for drug combinations: a review.
    Chang TT; Chou TC
    Acta Paediatr Taiwan; 2000; 41(6):294-302. PubMed ID: 11198934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug combination studies and their synergy quantification using the Chou-Talalay method.
    Chou TC
    Cancer Res; 2010 Jan; 70(2):440-6. PubMed ID: 20068163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.
    Zhang N; Fu JN; Chou TC
    Am J Cancer Res; 2016; 6(1):97-104. PubMed ID: 27073727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic potential of dual andrographolide and melatonin targeting of metastatic colon cancer cells: Using the Chou-Talalay combination index method.
    Banerjee V; Sharda N; Huse J; Singh D; Sokolov D; Czinn SJ; Blanchard TG; Banerjee A
    Eur J Pharmacol; 2021 Apr; 897():173919. PubMed ID: 33577837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.
    Zhao L; Wientjes MG; Au JL
    Clin Cancer Res; 2004 Dec; 10(23):7994-8004. PubMed ID: 15585635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
    Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
    Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 10. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of drug interactions.
    Bijnsdorp IV; Giovannetti E; Peters GJ
    Methods Mol Biol; 2011; 731():421-34. PubMed ID: 21516426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro.
    Chou TC; Tan QH; Sirotnak FM
    Cancer Chemother Pharmacol; 1993; 31(4):259-64. PubMed ID: 8422687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.
    Chou TC
    Am J Cancer Res; 2011; 1(7):925-54. PubMed ID: 22016837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mass-action law based algorithms for quantitative econo-green bio-research.
    Chou TC
    Integr Biol (Camb); 2011 May; 3(5):548-59. PubMed ID: 21403972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating response to antineoplastic drug combinations in tissue culture models.
    Reynolds CP; Maurer BJ
    Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.
    Xu JM; Azzariti A; Colucci G; Paradiso A
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):442-8. PubMed ID: 13680161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.
    Malyutina A; Majumder MM; Wang W; Pessia A; Heckman CA; Tang J
    PLoS Comput Biol; 2019 May; 15(5):e1006752. PubMed ID: 31107860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An improved model for the analysis of combined antimicrobials: a replacement for the Chou-Talalay combination index method.
    Anastasiadi M; Polizzi K; Lambert RJW
    J Appl Microbiol; 2018 Jan; 124(1):97-107. PubMed ID: 29080234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.